首站-论文投稿智能助手
典型文献
Structure genomics of SARS-CoV-2 and its Omicron variant:drug design templates for COVID-19
文献摘要:
Coronavirus disease 2019(COVID-19),caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has brought an unprecedented public health crisis and persistently threatens to humanity.With tireless efforts from scientists around the world,understanding of the biology of coronavirus has been greatly enhanced over the past 2 years.Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19.In this review,we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed.We present the examples of structure-based design of Pfizer's novel anti-SARS-CoV-2 drug PF-07321332(Paxlovid),Merck's nucleotide inhibitor molnupiravir(Lagevrio),and W116,an oral drug candidate for COVID-19.These examples highlight the importance of structure in drug discovery to combat COVID-19.We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies.
文献关键词:
作者姓名:
Can-rong Wu;Wan-chao Yin;Yi Jiang;H.Eric Xu
作者机构:
The CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China
引用格式:
[1]Can-rong Wu;Wan-chao Yin;Yi Jiang;H.Eric Xu-.Structure genomics of SARS-CoV-2 and its Omicron variant:drug design templates for COVID-19)[J].中国药理学报(英文版),2022(12):3021-3033
A类:
tireless,Lagevrio,W116
B类:
Structure,genomics,SARS,CoV,its,Omicron,design,templates,Coronavirus,disease,caused,by,severe,acute,respiratory,syndrome,coronavirus,has,brought,unprecedented,public,health,crisis,persistently,threatens,humanity,With,efforts,from,scientists,around,world,understanding,biology,been,greatly,enhanced,past,years,Structural,demonstrated,powerful,impact,uncovering,structures,functions,vast,majority,proteins,guided,development,drugs,vaccines,against,In,this,review,summarize,current,progress,structural,important,biological,issues,that,remain,addressed,We,present,examples,Pfizer,novel,PF,Paxlovid,Merck,nucleotide,inhibitor,molnupiravir,oral,candidate,These,highlight,importance,discovery,combat,also,discussed,recent,variants,implication,immunity,escape,existing,antibody,therapies
AB值:
0.632388
相似文献
Potential medicinal plants involved in inhibiting 3CLpro activity:A practical alternate approach to combating COVID-19
Fan Yang;Xiao-lan Jiang;Akash Tariq;Sehrish Sadia;Zeeshan Ahmed;Jordi Sardans;Muhammad Aleem;Riaz Ullah;Rainer W.Bussmann-The Medical Center of General Practice,Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital,Chengdu 610041,Sichuan Province,China;Xinjiang Institute of Ecology and Geography,Chinese Academy of Sciences,Urumqi 830041,Xinjiang Uygur Autonomous Region,China;Department of Biological Sciences,University of Veterinary and Animal Sciences,Ravi Campus,Pattoki 55300,Pakistan;Consejo Superior de Investigaciones Científicas,Global Ecology Unit,Centre for Ecological Research and Forestry Applications-Consejo Superior de Investigaciones Cientificas-Universitat Autònoma de Barcelona,Bellaterra,Barcelona 08193,Catalonia,Spain;Centre for Ecological Research and Forestry Applications,Cerdanyola del Vallès 08193,Catalonia,Spain;Department of Pharmacognosy,College of Pharmacy,King Saud University,Riyadh 11451,Saudi Arabia;Department of Ethnobotany,Institute of Botany,Ilia State University,Tbilisi 0105,Georgia
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Na-Na Zhang;Rong-Rong Zhang;Yi-Fei Zhang;Kai Ji;Xiao-Chuan Xiong;Qian-Shan Qin;Peng Gao;Xi-Shan Lu;Hang-Yu Zhou;Hai-Feng Song;Bo Ying;Cheng-Feng Qin-Department of Virology,State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd.,Suzhou,Jiangsu,China;School of Life Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,China;Institute of Systems Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
Jun Lan;Xinheng He;Yifei Ren;Ziyi Wang;Huan Zhou;Shilong Fan;Chenyou Zhu;Dongsheng Liu;Bin Shao;Tie-Yan Liu;Qisheng Wang;Linqi Zhang;Jiwan Ge;Tong Wang;Xinquan Wang-The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,China;Microsoft Research Asia,Beijing,China;Shanghai Synchrotron Radiation Facility,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai,China;Department of Chemistry,Tsinghua University,Beijing,China;Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,China
Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants,including Omicron sublineages
Lei Wang;Wangjun Fu;Linlin Bao;Zijing Jia;Yuxia Zhang;Yunjiao Zhou;Wei Wu;Jianbo Wu;Qianqian Zhang;Yidan Gao;Kang Wang;Qiao Wang;Chuan Qin;Xiangxi Wang-CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing,China;University of Chinese Academy of Sciences,Beijing,China;Key Laboratory of Human Disease Comparative Medicine,Chinese Ministry of Health,Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China;Changping Laboratory,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,School of Basic Medical Sciences,Shanghai Medical College,Fudan University,Shanghai,China
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Structures of the endogenous peptide-and selective non-peptide agonist-bound SSTR2 signaling complexes
Li-Nan Chen;Wei-Wei Wang;Ying-Jun Dong;Dan-Dan Shen;Jia Guo;Xuefei Yu;Jiao Qin;Su-Yu Ji;Huibing Zhang;Qingya Shen;Qiaojun He;Bo Yang;Yan Zhang;Qinglin Li;Chunyou Mao-Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital,Zhejiang University,School of Medicine,Hangzhou,Zhejiang,China;Department of General Surgery,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Center for Structural Pharmacology and Therapeutics Development,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,Zhejiang,China;The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Hangzhou,Zhejiang,China;Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou,Zhejiang,China;MOE Frontier Science Center for Brain Research and Brain-Machine Integration,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Zhejiang Provincial Key Laboratory of Immunity and Inflammatory diseases,Hangzhou,Zhejiang,China
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
Yang Yi;Meng Zhang;Heng Xue;Rong Yu;Yang-Oujie Bao;Yi Kuang;Yue Chai;Wen Ma;Jing Wang;Xiaomeng Shi;Wenzhe Li;Wei Hong;Junhua Li;Elishiba Muturi;Hongping Wei;Joachim Wlodarz;Szczepan Roszak;Xue Qiao;Hang Yang;Min Ye-State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;CAS Key Laboratory of Special Pathogens and Biosafety,Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China;University of Chinese Academy of Sciences,Beijing 100049,China;Faculty of Science and Technology,University of Silesia,Katowice 40-007,Poland;Department of Physical and Quantum Chemistry,Faculty of Chemistry,Wroclaw University of Science and Technology,Wroclaw 50-370,Poland
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。